OR WAIT null SECS
SAN DIEGO, CA – June 25, 2018 –
, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event. With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide. In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will support Synteract by sharing ideas, best practices in study designs, protocol review intended for pediatric treatment, and patient facing documents review to help increase recruitment and enhance the quality and benefit of pediatric clinical trials and pediatric research. Both organizations will capitalize on opportunities for innovation in leveraging their respective expertise to enable children and their families to take ownership of their health, provide meaningful input into regulations, and improve design and conduct of pediatric studies worldwide. “At iCAN, we are dedicated to advancing the health and well-being of children around the world. An important part of that is collaborating with established partners, such as Synteract in the pediatric clinical trials space,” said Leanne West, president of iCAN. “We look forward to working together to leverage Synteract’s extensive knowledge, industry experience, and drug development acumen to further advance pediatric clinical research and increase availability of medicines to help children.” Synteract has been at the forefront of working with sponsors in pediatric clinical trials for three decades, with 100 pediatric studies performed worldwide across multiple therapeutic indications. It recently announced pediatrics drug development as one of its focused therapeutic centers of development. Dr. Martine Dehlinger-Kremer heads up the pediatric center of development at Synteract, as vice president, Pediatric Development. She is also President of EUCROF, the European CRO Federation; Chair of the Pediatric Working Group of EUCROF since 2008, and Chair of the European Forum for GCP Children Medicines Working Party. She was appointed Observer Member of the Coordinating Group of Enpr-EMA, the European Network of Pediatric Research at the European Medicines Agency (EMA), in April 2018, and has been a member of Working Parties of Enpr-EMA for several years. ”At Synteract we remain committed to advancing standards and assisting sponsors to address growing needs for pediatric clinical research,” said Dr. Dehlinger-Kremer. “By partnering with iCAN, we gain access to its wide network of children and families spanning socioeconomic, cultural, and geographic backgrounds, which will be beneficial for the development of medicines for children. Our partnership with iCAN will be valuable in developing better, more appropriate protocols, study designs, patient facing documents and setting strategy for recruitment. It will also help us to further innovation in systems and treatments. It is another important step to show our commitment to this important population.” iCAN is supported by the Foundation for Children, the 501 (c) 3 nonprofit arm of the Connecticut Chapter of the American Academy of Pediatrics (CT-AAP).
With 800 staff members across 21 countries,
is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in pediatric, oncology and neuro degenerative indications, as well as rare and orphan and immunotherapy studies.